Exploring Partnership Governance in Global Health

BT Slingsby
Japan, with its unique chemical compounds, technologies, and knowhow, is an innovation leader in infectious disease drug creation.

Source: JPMA Guide 2010

JAPAN: New Drug Development World Ranking: No.3
Before GHIT Founded in 2013
GHIT Founding Partners
June 2013
USD 100M, 8 Partners
GHIT Funding Partners

June 2017

USD 350M, 26 Partners

including GHIT Replenishment

Full Partners

Public

Private

Full Partners

Full Partners

Associate Partners

Affiliate Partners

Sponsors

USD 350M, 26 Partners
GHIT Fund Portfolio

**Discovery**
- **Target Research Platform**
  - Malaria
- **Screening Platform**
- **Hit-to-Lead Platform**

**Preclinical**
- **Product Development Platform**

**Clinical**
- **Product Development Platform**

**Tuberculosis**
- **Chagas disease, Leishmaniasis**
- **NTDs**

**Dengue fever**
- **Leishmaniasis**
- **Soil-transmitted helminths**

For more details about each project, please visit the GHIT Fund Website: https://www.ghitfund.org/impact/portfolio/
GHIT Invested Clinical Trials

- **DSM265**
  - Disease: Malaria
  - Intervention: Drug
  - Development Stage: Phase III
  - Country: Peru

- **E1224**
  - Disease: Chagas disease
  - Intervention: Drug
  - Development Stage: Phase IIa
  - Country: Bolivia

- **BOLIVIA**

- **BURKINA FASO**

- **IVORY COAST**
  - **PZQ**
    - Disease: Schistosomiasis
    - Intervention: Pediatric Drug
    - Development Stage: Phase Iib
    - Country: Ivory Coast

- **TANZANIA**
  - **BK-SE36/CpG**
    - Disease: Malaria
    - Intervention: Vaccine
    - Development Stage: Phase Iib
    - Country: Burkina Faso, Uganda
  - **DAR-901**
    - Disease: Tuberculosis
    - Intervention: Vaccine
    - Development Stage: Phase Iib
    - Country: Tanzania
  - **(+)-SJ000557733**
    - Disease: Malaria
    - Intervention: Drug
    - Development Stage: Phase IIa
    - Country: TBC
GHIT Product Development Partners

41 Japanese Organizations
53 Non-Japanese Organizations
Items Discussed in GHIT Launch Committee

- Articles of Incorporation
- Corporate Entity and Governance Structure (Managing COI)
- Organizational Name & Logo
- Membership of Council, Board, Selection Committee and Advisory Panel
- Investment Scope and Mechanism
- Access Policy (Pricing, Licensing, IP data)
- Launch Preparation & Communication Strategy

(Images of GHIT Fund logo)
Successes

Defined and implemented:

- A balance of power among stakeholders: representation in governance (i.e., Council, Board, Selection Committee, Management)

COI Management

A partnership structure for pharma to work with government on R&D: From in-kind to cash, firewall on decision-making, no secondment

Power Balance

A balance of power among stakeholders: representation in governance (i.e., Council, Board, Selection Committee, Management)
Successes

Defined and implemented:

COI Management
A partnership structure for pharma to work with government on R&D: From in-kind to cash, firewall on decision-making, no secondment

Power Balance
A balance of power among stakeholders: representation in governance (i.e., Council, Board, Selection Committee, Management)

Impact Alignment
A balance between national and global interests: investment criterion of national technologies aligned with global portfolio
Challenges

Legal : Governance
Creating an organization aligned with international standards based on Japanese law

Diversity Management
Ensuring a common understanding of governance among and in all governing bodies

Leadership Sustainability
Sustainability of global and multi-sectorial leadership throughout governing bodies committed in terms of content and time